Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Survivorship challenges in young patients with breast cancer

Cynthia Villarreal-Garza • 13 Mar 2025
BCC 2025
Breast Cancer

Cynthia Villarreal-Garza, MD, DSc, TecSalud, Monterrey, Mexico, emphasizes the importance of highlighting long-term toxicities in young patients with breast cancer, who often experience more severe side effects due to prolonged and more intense treatments. Proactive efforts are needed to identify these toxicities, as the survivorship phase often overlooks the unique challenges faced by young patients. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Cynthia Villarreal-Garza

Evaluating sexual dysfunction in young women with breast cancer
0:55
Evaluating sexual dysfunction in young women with breast cancer
Cynthia Villarreal-Garza • 13 Mar 2025
Unmet needs in younger patients with breast cancer
1:43
Unmet needs in younger patients with breast cancer
Cynthia Villarreal-Garza • 13 Mar 2025
Improving access to endocrine therapies in Mexico
1:00
Improving access to endocrine therapies in Mexico
Cynthia Villarreal-Garza • 25 Mar 2021
Prescribing practices of endocrine therapy for premenopausal breast cancer patients in Mexico
4:05
Prescribing practices of endocrine therapy for premenopausal breast cancer patients in Mexico
Cynthia Villarreal-Garza • 25 Mar 2021

Related Videos

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals